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In a recent paper, renal impairment is correctly described as a common complica-
tion of symptomatic myeloma (20 -- 40%) needing dialysis. Significant improve-
ment has been attributed to novel therapeutic chemotherapy regimens coupled
with extrarenal free light chain removal obtained by plasma exchange or dialysis [1].
As nephrologists, we would like to stress the importance of recognizing early
symptoms of renal impairment other than by measuring renal function as glomeru-
lar filtration rate (GFR) [2]. An increase in serum creatinine and/or a decrease in
GFR are not the only markers of renal impairment in patients with multiple mye-
loma. Although a serum creatinine > 2 mg/dl is one of the hypercalcemia, renal
impairment, anemia, bone disease (CRAB) diagnostic criteria for symptomatic mye-
loma requiring therapy, it has been stated that “a variety of other types of end-organ
dysfunctions can occur and lead to a need for therapy. Such a dysfunction is suffi-
cient to support classifications of myeloma if proven to be myeloma-related” [3].
Tubular dysfunctions, and mainly proximal tubular dysfunctions with the picture
of complete or incomplete Fanconi syndrome, constitute such “other end-organ
dysfunctions” [1-3].
As far as the kidney is concerned, it is important to have early indicators of tubu-
lar dysfunction. This includes hypophosphatemia, hypouricemia, hypokalemia and
metabolic acidosis coupled with urine loss of phosphate, urate, potassium, bicarbon-
ate, low-molecular-weight proteins and glycosuria (in the presence of normal blood
glucose levels). Therefore, even if free light chains detected in the urine (Bence Jones
proteinuria) is not a sign of renal damage by itself, its transcellular “traffic” may
cause tubular damage, eventually leading to tubular crystal-storing histiocytosis
and Fanconi syndrome. Subsequently, tubular casts precipitating in the distal tubule
may cause acute renal failure of the classical ‘myeloma kidney’ [4,5].
Therefore, a delay in diagnosis could allow irreversible kidney damage to occur
and might shorten patient survival.
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Authors’ reply
We agree with Stratta et al. that patients with an otherwise-
indolent plasma-cell dyscrasia may present with renal
dysfunction, which may not be reflected in the levels of
serum creatinine and epidermal growth factor receptor.
We only briefly report Fanconi’s syndrome in our review [1];
however, the term “monoclonal gammopathy of renal
significance” (MGRS) has been introduced to include renal
pathology which is not related to overt myeloma [2].
A position paper on the management of MGRS also includes
an opinion on the management of Fanconi’s syndrome in
patients with monoclonal gammopathy [3]. Physicians should
consider the possibility of this syndrome in patients
presenting with unexplained osteoporosis, hypophosphatemia,
hypouricemia, hypokalemia and metabolic acidosis together
with a monoclonal gammopathy. Urine studies for phosphate,
urate, potassium, bicarbonate, low-molecular-weight proteins
and glycosuria (in the presence of normal blood glucose
levels) should be considered. Early recognition may lead to
effective intervention although there is limited experience
regarding the treatment of this syndrome.
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